| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/13/2003 | WO2002060454B1 Use of dinucleoside polyphosphate to stimulate removal of fluid in retinal disorders |
| 02/13/2003 | WO2002060427A3 Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds |
| 02/13/2003 | WO2002059082A8 Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands |
| 02/13/2003 | WO2002055661A3 Fatty acid synthase inhibitors |
| 02/13/2003 | WO2002055492A3 An improved process for preparing pure ondansetron hydrochloride dihydrate |
| 02/13/2003 | WO2002055068A3 Cysteine for oral administration for dry eye treatment |
| 02/13/2003 | WO2002051388A3 Treatment of inoperable tumors by stereotactic injection of microspheres |
| 02/13/2003 | WO2002047604A3 Novel use of chalcone class compounds for inhibiting tumoral mass vascularization |
| 02/13/2003 | WO2002046192A3 Thioether substituted imidazoquinolines |
| 02/13/2003 | WO2002043765A9 Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
| 02/13/2003 | WO2002040462A3 Cysteine protease inhibitors |
| 02/13/2003 | WO2002040056A8 Carrageenan viscoelastics for ocular surgery |
| 02/13/2003 | WO2002038141A9 Compositions and methods for treatment of mild cognitive impairment |
| 02/13/2003 | WO2002037927A3 Compounds and methods for promoting smoking cessation |
| 02/13/2003 | WO2002036124A3 Treatment and method using loratadine and montelukast |
| 02/13/2003 | WO2002028382A9 Compositions for injection or intravenous administration for the treatment of internal infection or inflammation in humans and animals |
| 02/13/2003 | WO2002028366A9 Devices and methods for management of inflammation |
| 02/13/2003 | WO2002026325A9 Restoration of perturbed barrier function by application of antiandrogens |
| 02/13/2003 | WO2002015942A8 Method for the identification of agents that inhibit or promote cataracts and uses thereof |
| 02/13/2003 | WO2002013830A1 Cytokine production inhibitors |
| 02/13/2003 | WO2002013791A3 Steroid hormones as transfer agents |
| 02/13/2003 | WO2002009755A3 Apo-2l receptor agonist and cpt-11 synergism |
| 02/13/2003 | WO2002003920A8 Method for treatment of reactive arthritis or bursitis |
| 02/13/2003 | WO2001092331A8 Compositions and methods for the treatment of immune related diseases |
| 02/13/2003 | WO2001087286A3 Antisense enzyme inhibitors for improving pharmacokinetics of a drug |
| 02/13/2003 | WO2001072754A8 Alkylated imidazopyridine derivatives |
| 02/13/2003 | US20030033089 Substituted quinazolines and analogs and the use thereof |
| 02/13/2003 | US20030032945 Coated filter bag material for oral administration of medicament in liquid and methods of making same |
| 02/13/2003 | US20030032943 Biocompatible, injectable aqueous solution for use in ultrasound energy assisted surgery |
| 02/13/2003 | US20030032917 Use of a blood-flow decrease preventing agent in conjunction with insufflating gas |
| 02/13/2003 | US20030032834 Aminoalcohol derivatives |
| 02/13/2003 | US20030032827 Lipoxin compounds and their use in treating cell proliferative disorders |
| 02/13/2003 | US20030032824 Meiosis regulating compounds |
| 02/13/2003 | US20030032813 Parathyroid hormone receptor-mediated adenylate cyclase formation; treating osteoporosis |
| 02/13/2003 | US20030032812 Cyclobutaindolecarboxamide compounds |
| 02/13/2003 | US20030032804 Methods of treating periodontal disease |
| 02/13/2003 | US20030032803 Novel amide derivatives as inhibitors of matrix metalloproteinases, TNF-alpha, and aggrecanase |
| 02/13/2003 | US20030032800 Dibenzo(b,f)azepine derivatives and their preparation |
| 02/13/2003 | US20030032799 For cancer treatment |
| 02/13/2003 | US20030032775 Effector proteins of rapamycin |
| 02/13/2003 | US20030032678 Comprises plant extracts/oils (isopropyl-o-cresol) reacted with sodium chloride to form sodium-o-cresolate, to provide antimicrobial function |
| 02/13/2003 | US20030032677 Contains peroxidic species or reaction products resulting from oxidation of geraniol via ozone; for treating horses infected with Sarcocystis protozoal infections |
| 02/13/2003 | US20030032676 Administering tamoxifen to modulate exciatory amino acid release; for treating and preventing cerebral hypoxic or ischemic damage; neuroprotection |
| 02/13/2003 | US20030032675 Apparatus for transporting thyroid hormone drug formulations from a blender to a tableting machine; especially for treatment of hypothyroidism in cats and dogs |
| 02/13/2003 | US20030032674 Use of unsaturated fatty acids to treat severe inflammatory diseases |
| 02/13/2003 | US20030032673 Therapeutic strategies for prevention and treatment of alzheimer's disease |
| 02/13/2003 | US20030032670 Monohydrate of cis-lithium-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl)cyclohexanecarboxylate |
| 02/13/2003 | US20030032668 Water soluble bactericide and producing method thereof |
| 02/13/2003 | US20030032666 Crystalline forms |
| 02/13/2003 | US20030032665 Method of inhibiting matrix metalloproteinases |
| 02/13/2003 | US20030032664 Method of cancer treatment |
| 02/13/2003 | US20030032663 Inhibition of the interaction of RAGE with its ligands; treatment acute and chronic inflammation, the development of diabetic late complications, Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis. |
| 02/13/2003 | US20030032661 Treatment of generalized seizures (absences, also atypical absences, myoclonic, clonic, tonic, and tonic-clonic seizures), focal (simple and complex focal) and secondary generalized seizures. |
| 02/13/2003 | US20030032660 Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof |
| 02/13/2003 | US20030032659 Stabilization of retinoid compounds |
| 02/13/2003 | US20030032658 Muscarinic receptor agonists |
| 02/13/2003 | US20030032656 2-Amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors |
| 02/13/2003 | US20030032655 Heme oxygenase-1 inducers or induction enhancers |
| 02/13/2003 | US20030032654 Useful for the treatment or prevention of asthma and other allergic diseases. |
| 02/13/2003 | US20030032653 Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production |
| 02/13/2003 | US20030032652 Hydroxamic and carboxylic acid derivatives |
| 02/13/2003 | US20030032651 Intrathecal analgesia method |
| 02/13/2003 | US20030032650 Adenosine receptor antagonists, especially aminophyllline; can also be used to help sustain a kidney for transplant purposes. |
| 02/13/2003 | US20030032647 Aromatic nitrogen-containing 6-membered cyclic compounds |
| 02/13/2003 | US20030032646 Use of serotonergic compound for a method of treatment of hot flushes in post-menopausal women |
| 02/13/2003 | US20030032645 Aryl-8-azabicyclo [3.2.1] octanes for the treatment of depression |
| 02/13/2003 | US20030032643 Pharmaceutically active morpholinol |
| 02/13/2003 | US20030032642 Treating psoriasis, a disease in which angiogenesis is associated with raised CXCR2 chemokine levels, or COPD. |
| 02/13/2003 | US20030032641 Certain salts of discodermolide acid, pharmaceutical compositions containing them and their use in treating tumors |
| 02/13/2003 | US20030032640 Novel composition |
| 02/13/2003 | US20030032638 An aerosol for inhalation therapy, wherein the aerosol comprises particles comprising at least 10 percent by weight of a benzodiazepine such as clonazepam, flunitrazepam or flurazepam. |
| 02/13/2003 | US20030032636 For the treatment of depression and other affective disorders. |
| 02/13/2003 | US20030032635 Heterocyclic esters and amides |
| 02/13/2003 | US20030032634 Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance |
| 02/13/2003 | US20030032633 Use of the active fraction (-)- Olivil as an antioxidant or free radical scavenger. |
| 02/13/2003 | US20030032632 Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate |
| 02/13/2003 | US20030032631 Method of treatment of cancer by controlling graft-versus-leukemia using topical active corticosteriods |
| 02/13/2003 | US20030032630 Use of a 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor NF-kappaB |
| 02/13/2003 | US20030032629 While minimizing the occurrence of or potential for adverse gastrointestinal effects; administering a bisphosphonate such as alendronate, pharmaceutically acceptable salts thereof, and mixtures thereof. |
| 02/13/2003 | US20030032628 Wet granulation formulation for bisphosphonic acids |
| 02/13/2003 | US20030032627 Especially due to osteoarthrosis, osteochondrosis, navicular disease or enthesopathy of the bony insertions of the tendons, of the ligaments, or of the aponeurosis, particularly in horses |
| 02/13/2003 | US20030032626 Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
| 02/13/2003 | US20030032625 Succinimide and maleimide derivatives and their use as topoisomerase II catalytic inhibitors |
| 02/13/2003 | US20030032623 E.g., 1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea; useful as therapeutic agents for autoimmune diseases such as rheumatoid arthritis. |
| 02/13/2003 | US20030032621 Means for regulating hematopoietic differentiation |
| 02/13/2003 | US20030032620 Efficient incorporation in vitro of thymidine, glucosamine and leucine in fibroblast macromolecules of the human cutis. Local application of this compound stimulates fibroblast metabolism. |
| 02/13/2003 | US20030032619 Pharmaceutical composition |
| 02/13/2003 | US20030032618 Pharmaceutical combinations |
| 02/13/2003 | US20030032617 Administering nicotinamide, a nicotinamide agonist, a nicotinamide derivative, a nicotinamide metabolite or prodrugs thereof. |
| 02/13/2003 | US20030032616 Increasing cerebral bioavailability of drugs |
| 02/13/2003 | US20030032614 Method of treating respiratory distress using synthetic polynucleic acids |
| 02/13/2003 | US20030032612 Inhibit expression of a gene in the operon; reducing bacterial resistance to antibiotics |
| 02/13/2003 | US20030032610 Administering one or more oligonucleotides which share at least 50% nucleotide sequence identity with (TTAGGG)n or oligonucleotides which share at least 50% nucleotide sequence identity with the human telomere overhang repeat. |
| 02/13/2003 | US20030032604 Smilagenin and its use |
| 02/13/2003 | US20030032600 Taste masked liquid pharmaceutical compositions |
| 02/13/2003 | US20030032596 Administering a compound that modulates the synthesis or expression of a target cellular gene, especially a Src kinase. |
| 02/13/2003 | US20030032595 Compositions and methods relating to glucose metabolism, weight control, and food intake |
| 02/13/2003 | US20030032593 Transporters comprising spaced arginine moieties |
| 02/13/2003 | US20030032585 The use of trefoil factor 2 (TFF2) peptides increasing the viscosity of mucus layers in mammals |
| 02/13/2003 | US20030032584 Inhibiting abnormal cellular proliferation in a mammal; and a method of inhibiting replication of a virus in a mammal. |